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implantation. Although VADs have been shown to be
able to reverse end-organ failure in some patients,1,2 the
pathophysiologic mechanisms of end-organ failure and
its recovery are not fully understood, and clinical mark-
ers and thresholds beyond which recovery is unlikely to
occur are often lacking.
One of the crucial major organs determining patient sur-
vival during VAD support is the liver. However, the role of
hepatic function in patients with a VAD and the limits of
reversibility are poorly understood. In a state of acute cir-
culatory failure, decreased hepatic blood flow and
increased hepatic venous pressure can lead to cellular
hypoxia3 and a clinical picture similar to viral hepatitis,
frequently called “ischemic hepatitis.”4,5 Common abnor-
malities include the elevation of prothrombin time, liver
enzymes, and sometimes bile duct enzymes and bilirubin.
V entricular assist devices (VADs) have become anaccepted and effective therapy as a bridge to cardiac
transplantation in selected patients with end-stage heart
failure who would otherwise have died of their cardiac
diseases. However, there remains the risk of dying of
end-organ damage already present at the time of
Patient selection is crucial for the success of ventricular assist devices as
a bridge to heart transplantation. Purpose: The objective of this study
was to identify preoperative markers for survival and end-organ recov-
ery in patients having a ventricular assist device. Methods: A retrospec-
tive study was performed on 32 severely ill patients with end-stage car-
diac failure being mechanically bridged to heart transplantation with
the Thoratec Ventricular Assist Device System (Thoratec Laboratories
Corporation, Pleasanton, Calif) in a single center between 1984 and
1995. The preoperative cardiac index averaged 1.6 L/min per square
meter with a pulmonary capillary wedge pressure of 29 mm Hg. Because
of a high incidence of hepatic or renal dysfunction, or both (total biliru-
bin: 3.5 ± 6.2 mg/dL; creatinine: 2.0 ± 1.3 mg/dL), biventricular support
was used in most patients (28/32). A total of 30 preoperative and 4 peri-
operative variables were evaluated for their association with survival
and liver recovery. Results: Nineteen patients (59.4%) survived to trans-
plantation and 13 died. All 19 patients undergoing transplantation were
discharged alive with a 1-year survival of 94.4%. All patients without
liver recovery died of multiorgan failure. Direct and indirect bilirubin
measurements were the only significant predictors for survival to dis-
charge (P = .036, .045); all other factors failed to show significance. As
direct bilirubin levels increased (normal range, 3 times normal, and >3
times normal), patient survival decreased (82%, 56%, and 33%, respec-
tively). In addition, bilirubin and liver enzyme levels before insertion of
the assist device were significantly associated with liver recovery during
support with the device. Conclusion: In our patient population with ven-
tricular assist devices, liver function is the most predictive factor of
patient survival in bridging to transplantation. (J Thorac Cardiovasc
Surg 1998;116:633-40)
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Because of the importance of patient selection, a num-
ber of publications have evaluated pre-VAD markers of
survival in patients with significant end-organ failure,
but with no consistent findings.1,6-9 This article focuses
on the importance of liver function in patients having a
VAD. On the basis of a single-center experience, we ana-
lyze different liver function variables to assess which of
them are predictive of patient survival and liver recovery.
Methods
Patients. At California Pacific Medical Center, from 1984
to 1995, 48 patients with acute or chronic heart failure were
mechanically supported with the Thoratec VAD System
(Thoratec Laboratories Corporation, Pleasanton, Calif). Of
these, 32 patients (29 male and 3 female) received the device
as a bridge procedure to heart transplantation and will be ana-
lyzed further in this study; the remaining 16 patients were
supported after cardiotomy for weaning from cardiopul-
monary bypass and are not included in this study. The ages of
the bridge-to-transplant group ranged from 30 to 61 years
with a mean age of 46 years. Dilated cardiomyopathy was
diagnosed in 13, ischemic cardiomyopathy in 8, acute
myocardial infarction in 8 patients, and postpartum car-
diomyopathy, hemochromatosis, and mitral valve disease in 1
patient each. Six patients had undergone other cardiac opera-
tions before VAD implantation. Average body surface area
was 1.9 m2 (range 1.6-2.6 m2) and average weight was 78 kg
(range 51-126 kg).
Preoperative status and indication for support. All
patients in this study were candidates for cardiac transplanta-
tion and were selected for VAD support at a stage of the dis-
ease where death or permanent end-organ damage was likely
to occur before a donor heart was available. Hemodynamic
guidelines for implantation were cardiac index less than 1.8
L/min per square meter, mean arterial pressure less than 70
mm Hg, and left atrial pressure greater than 20 mm Hg
despite appropriate use of conventional therapies.
Before implantation, all patients were receiving maximal
inotropic support and the average cardiac index was 1.6
L/min per square meter with an average pulmonary capillary
wedge pressure of 28.9 mm Hg. Fifty percent of patients had
prior cardiac arrests, 88% were supported with intra-aortic
balloon pumps, and 69% were intubated and mechanically
ventilated. More than half of the patients had substantial liver
failure before implantation, with 18 patients (56%) having
elevation of both transaminases and 19 (59%) having patho-
logic total bilirubin levels.
Mechanical circulatory support system. The Thoratec
VAD System was used as a biventricular system in 28 patients
(88%) and as a left VAD in 4 patients. The system consists of
paracorporeally placed prosthetic ventricles with a 65-mL
stroke volume connected to the heart and great vessels via
cannulas crossing the chest wall and a pneumatic drive con-
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Table I. Analysis of continuous variables measured before VAD insertion between survivors and nonsurvivors and
between patients with liver recovery and without liver recovery
Pre-VAD variable All patients Survivors Nonsurvivors P value Liver recovery No liver recovery P value
Age (y) 46.0 ± 9.6 45.4 ± 9.0 46.8 ± 10.6 >.2 46.4 ± 9.3 41.3 ± 8.7 .162
Weight (kg) 77.9 ± 15.3 81.1 ± 17.5 73.4 ± 10.6 >.2 81.3 ± 16.2 70.4 ± 9.5 .099
BSA (m2) 2.0 ± 0.2 2.0 ± 0.2 1.9 ± 0.7 >.2 2.01 ± 0.2 1.87 ± 0.2 .199
CI (L/min/m2) 1.6 ± 0.7 0.9 ± 0.7 1.7 ± 1.0 .033 1.0 ± 0.8 1.7 ± 1.0 .181
PCWP (mm Hg) 28.9 ± 6.2 30.3 ± 7.4 27.1 ± 3.9 >.2 30.3 ± 7.1 26.0 ± 3.9 >.2
Hct (%) 33.2 ± 5.1 33.4 ± 4.9 33.0 ± 5.6 >.2 33.8 ± 5.1 33.6 ± 5.4 >.2
WBC (nl) 13.6 ± 5.7 15.0 ± 6.4 12.3 ± 4.3 >.2 14.3 ± 6.5 14.1 ± 4.1 >.2
Platelets (nl) 144 ± 95 171 ± 107 107 ± 55 .112 166 ± 105 95 ± 63 .103
PT (s) 15.7 ± 3.4 15.0 ± 2.8 16.6 ± 4.0 >.2 15.0 ± 2.8 17.1 ± 3.8 >.2
AST (U/L) 422 ± 793 272 ± 573 631 ± 1013 >.2 248 ± 546 985 ± 1176 .016
ALT (U/L) 387 ± 782 222 ± 415 620 ± 1097 >.2 211 ± 405 914 ± 1263 .016
AP (U/L) 73 ± 41 70 ± 20 78 ± 60 >.2 69 ± 19 94 ± 72 >.2
GGT (U/L) 76 ± 76 71 ± 33 84 ± 117 >.2 70 ± 32 112 ± 142 >.2
LD (U/L) 831 ± 884 642 ± 555 1092 ± 1178 >.2 605 ± 539 1578 ± 1293 .038
Protein (mg/dL) 5.5 ± 0.9 5.5 ± 0.9 5.6 ± 0.8 >.2 5.5 ± 0.9 5.3 ± 0.8 >.2
Albumin (mg/dL) 3.0 ± 0.8 3.0 ± 0.6 3.0 ± 1.0 >.2 3.0 ± 0.7 2.8 ± 0.9 >.2
Total bilirubin (mg/dL) 3.5 ± 6.2 1.6 ± 1.6 5.8 ± 9.0 .062 1.7 ± 1.8 8.5 ± 10.7 .001
Direct bilirubin (mg/dL) 1.6 ± 3.0 0.7 ± 0.8 2.8 ± 4.3 .036 0.7 ± 0.9 4.0 ± 4.9 .001
Indirect bilirubin (mg/dL) 2.0 ± 3.5 0.9 ± 0.9 3.4 ± 5.1 .045 1.0 ± 1.1 4.5 ± 6.0 .008
BUN (mg/dL) 36.2 ± 19.7 33.7 ± 17.9 39.6 ± 22.2 >.2 33.2 ± 17.7 46.9 ± 24.4 .165
Creatinine (mg/dL) 2.0 ± 1.3 1.9 ± 0.8 2.0 ± 1.8 >.2 1.9 ± 0.8 2.5 ± 2.2 >.2
AST/LD ratio 0.38 ± 0.3 0.33 ± 0.27 0.46 ± 0.44 >.2 0.32 ± 0.27 0.58 ± 0.50 .091
ALT/LD ratio 0.40 ± 0.5 0.36 ± 0.40 0.45 ± 0.58 >.2 0.34 ± 0.39 0.64 ± 0.65 .177
VAD, Ventricular assist device; BSA, body surface area; CI, cardiac index; PCWP, pulmonary capillary wedge pressure; Hct, hematocrit; WBC, white blood cells; PT,
prothrombin time; AST, aspartate transaminase; ALT, alanine transaminase; AP, alkaline phosphatase; GGT, gamma-glutamyl transferase; LD, lactate dehydrogenase;
BUN, blood urea nitrogen. 
sole.10 The left VAD inflow was achieved from the left ven-
tricular apex in 24 patients and from the left atrium in 8
patients; the right VAD inflow was from the right atrium; out-
flow of the VADs was through 14-mm preclotted polyester
grafts to the ascending aorta and pulmonary trunk, respec-
tively. The average support duration in the 11-year study period
was 18.5 days with a maximum of 149 days.
The study was conducted under investigational device
exemption regulations, with protocol and patient consent
forms approved by the institutional review board of the hospi-
tal and the US Food and Drug Administration. Informed con-
sent was obtained from either the patient or next of kin.
Factors analyzed. The following 30 preoperative factors
were evaluated regarding their association with 2 end points
(patient survival to discharge and liver recovery): age, sex, body
surface area, weight, diagnosis, cardiac index (either measured
by thermodilution or, in ventricular fibrillation, considered 0),
pulmonary capillary wedge pressure, pre-VAD cardiac opera-
tions, preoperative mechanical ventilation, preoperative intra-
aortic balloon pump, pre-VAD cardiac arrest, previous support
with a different system such as a centrifugal pump or extracor-
poreal membrane oxygenation, and 18 laboratory values deter-
mined directly before implantation of the device (Table I).
Additionally, several intraoperative and postoperative factors
were analyzed: inflow cannulation site on the left side, univen-
tricular or biventricular support, and reoperation for bleeding.
Liver recovery was defined as the return of the transaminas-
es (aspartate aminotransferase [AST] and/or alanine amino-
transferase [ALT]) to within normal limits within a maximum
of 14 days after implantation, regardless of subsequent death
due to reasons other than liver failure. Two of the 32 patients
were excluded from this subanalysis because liver function
first recovered and then deteriorated again in association with
other complications; one patient who died during the opera-
tion was also excluded. To analyze the time course of liver
recovery, total bilirubin and AST concentrations during the
first 3 weeks of support were also evaluated in all patients
who were supported by the device for 7 days or more.
Statistical methods. Comparisons of continuous variables
between survivors and nonsurvivors and between patients with
and without liver recovery, respectively, were performed with
a Mann-Whitney test. For comparisons of discrete variables,
Pearson’s c 2 test and Fisher’s exact test were used. In addition,
patients were divided into 3 groups on the basis of total and
direct bilirubin values: normal, up to 3 times normal, and more
than 3 times normal. For these groups, univariate logistic
regression was carried out to identify odds ratios. Multivariate
logistic regression of the data was not performed because of
the small numbers of patients. In the analysis of laboratory fac-
tors, 1 patient had to be excluded because no preoperative tests
were available. All statistical analyses were performed with the
Crunch statistical data package (Crunch Software Corporation,
Oakland, Calif) on a standard personal computer.
Results
Survival. Of the 32 patients receiving a VAD as a
bridge to transplantation, 19 (59.4%) survived to trans-
plantation and 13 (40.6%) died while being supported
with the device. All patients without liver recovery died
of multiorgan failure associated with highly pathologic
liver function values during VAD support. All 19
patients who survived to receive a heart transplant were
subsequently discharged from the hospital. In the late
follow-up period, 5 patients died 6 months and 2, 7, 9,
and 11 years after transplantation, respectively, giving
a 1-year survival after transplantation of 94.4%. Causes
of death while supported with the device were multior-
gan failure (7), sepsis (3), pneumonia (1), pulmonary
embolism (1), and right ventricular failure (1).
Association of preoperative factors with survival.
The analysis of preoperative factors is shown in Tables I
and II. In general, the average values measured in nonsur-
vivors appeared different from those in the survivors, but
as a result of high standard deviations these differences
were not statistically significant. Only direct and indirect
bilirubin values were significant, with group averages
approximately 4 times higher in the nonsurvivors (2.8 ±
4.3 and 3.4 ± 5.1 mg/dL, respectively) compared with
those of the survivors (0.7 ± 0.8 and 0.9 ± 0.9 mg/dL); the
difference in total bilirubin values approached signifi-
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Table II. Analysis of discrete factors before VAD
insertion between survivors and nonsurvivors
Non- Survivors 
Survivors survivors (%) P value
Diagnosis
Dilated cardiomyopathy 7 6 53.8 >.2
Acute myocardial 6 2 75.0
infarction
Ischemic cardiomyopathy 5 3 62.5
Other 1 2 33.3
Previous cardiac operation
Yes 2 4 33.3 .194
No 17 9 66.7
Preop cardiac arrest
Yes 9 7 56.3 >.2
No 10 6 62.5
Preop IABP
Yes 16 12 57.1 NA
No 3 1 75.0
Previous support with 
other system
Yes 1 3 25.0 NA
No 18 10 64.3
Preop mechanical 
ventilation
Yes 6 4 60.0 >.2
No 13 9 59.1
Sex
Male 17 12 58.6 NA
Female 2 1 66.7
IABP, Intra-aortic balloon pump; NA, test not applicable because of small
number in 1 group.
cance with a P value of .06 (Table I). Cardiac index
between the groups was also significantly different, but
with the survivors having a lower cardiac index. Leaving
out patients in ventricular fibrillation before implantation
(where cardiac index is assumed to be 0) and calculating
only the values measured by thermodilution, the differ-
ence was no longer statistically significant (10 survivors
with an average cardiac index of 1.4 ± 0.3 L/min per
square meter versus 9 nonsurvivors with an average car-
diac index of 1.9 ± 0.8 L/min per square meter).
Figs 1 and 2 show the values of pre-VAD total and
direct bilirubin of all patients individually on the left and
their survival divided into 3 groupings (normal range, up
to 3 times normal, more than 3 times normal) on the
right. The survival decreased stepwise from 82% to 56%
to 33% with increasing direct bilirubin levels (Fig 2).
The differences between the groups for both variables
were significant (see illustrations), although when total
bilirubin is analyzed, survival remained at 69% to 70%
until values of more than 3 times normal were achieved,
at which point survival decreased to only 25%.
Association of intraoperative and postoperative
factors with survival. As shown in Table III, there was
no statistically significant association between intraoper-
ative and postoperative factors and survival; however, of
4 patients who needed reintervention for bleeding, only
1 survived. The 3 who died had extremely high preoper-
ative total bilirubin levels, with a median of 6.2 mg/dL.
Association of preoperative factors with liver
recovery. The results of the analysis between patients
with and without liver recovery are given in Table I on
the right side. Patients with high total, direct, and indi-
rect bilirubin, AST, ALT, and lactate dehydrogenase
(LD) levels had a significantly higher likelihood of
dying of liver failure than did those without elevated
levels. Weight and AST/LD ratio were approaching sig-
nificance (ie, P value between .1 and .05).
Postimplantation course. The change of total biliru-
bin and AST in survivors and nonsurvivors during the
first 3 weeks of support is depicted in Fig 3. In the
majority of survivors, total bilirubin level rose slightly
during the first few days and recovered to normal or
near-normal values within 7 to 10 days of support;
however, in most nonsurvivors it increased to highly
pathologic values during this period. AST showed a
gradual decline to normal values within approximately
10 days in survivors, whereas there was high variability
and frequently initial increase in nonsurvivors.
Discussion
Analysis for patient survival. This study shows that
preimplantation liver function has an important impact
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Fig 1. Pre-VAD total bilirubin in survivors and nonsurvivors. All patients’ individual values are depicted on the
left (P value: Mann-Whitney test). Survival in percent of patients divided into 3 groupings of normal, 3 times nor-
mal or less, and greater than 3 times normal range is shown on the right. Logistic regression revealed a signifi-
cant difference between these groupings (P = .04) with an odds ratio of 3.3 (95% confidence interval: 1.05-10.32).
on the survival of patients undergoing mechanical
bridging to transplantation. Both the direct and indirect
fractions of bilirubin were significantly associated with
survival in our patients. Total bilirubin failed to show
significance and had a slightly higher P value (.062)
than either of its portions. This difference was due to 2
patients in whom only the total bilirubin level was avail-
able for analysis. Omitting these patients, total bilirubin
was also significantly (P = .022) related to survival.
A low preoperative direct bilirubin level appears to
be the best predictor of survival in our study. In the 3
groupings (Fig 2), the odds ratio for direct bilirubin
level was 3.0, indicating that, with all other factors
remaining equal, for each categoric increase in direct
bilirubin, a patient was 3 times less likely to survive. In
our study population, patients with a preoperative
direct bilirubin level of more than 3 times normal had a
survival of 33.3%, and patients having a total bilirubin
level of more than 3 times normal had a survival of
only 25%, compared with 82% and 70% survival-to-
transplantation for patients with normal direct and total
bilirubin levels, respectively. However, as the left sides
of Figs 1 and 2 illustrates best, even patients with
extremely elevated levels have a chance to survive. The
100% posttransplantation survivals (through hospital
discharge) achieved with these patients indicate that
preoperative liver dysfunction is no longer an issue in
patients who survived with the aid of VAD support to
qualify for heart transplantation.
A number of studies have previously been published
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Fig 2. Pre-VAD direct bilirubin in survivors and nonsurvivors. Analogous to Fig 1, individual values are shown
on the left (P value: Mann-Whitney test), survival in percent of patients divided into 3 groupings of normal, 3
times normal or less, and greater than 3 times normal range on the right. With logistic regression, difference
between the groupings was significant (P = .04) with an odds ratio of 3.0 (95% confidence interval: 1.07-8.31).
Table III. Analysis of intraoperative and postoperative
factors between survivors and nonsurvivors
Discrete Non- Survivors 
variables Survivors survivors (%) P value
Univentricular or 
biventricular support
LVAD 3 1 75.0 NA
BVAD 16 12 57.1
Cannulation site left 
inflow
Left ventricular apex 13 10 56.5 >.2
Left atrium 6 3 66.7
Reoperation for bleeding
Yes 1 3 25.0 NA
No 18 10 64.3
LVAD, Left ventricular assist device; BVAD, biventricular assist device; NA,
test not applicable because of small number in 1 group.
on patient selection for VAD support—with the Thoratec
VAD,1 with other devices,2,6,8,9,11 or with mixed device
populations.7,12,13 In some of these reports, a statistical
evaluation of preoperative risk factors has been per-
formed, but only the St Louis group,7 the Columbia
group,9 and the Thoratec multicenter1 results give statis-
tically significant predictors for survival.
In the St Louis data, white blood count, platelet
count, and preimplantation dialysis were significantly
associated with survival.7 These factors were not sig-
nificant in our analysis (however, pre-VAD dialysis was
not evaluated). The lack of significance of liver func-
tion tests in the St Louis series might be due to a dif-
ferent patient selection regimen resulting in fewer
patients with severe liver failure, as the mean bilirubin
level of the nonsurvivors was 1.2 mg/dL, compared
with 5.8 mg/dL in the present study. Preoperative
hepatic function in our patient population is also more
severely compromised than in other studies reported in
the literature,2,14, 15 implying that some patients in this
report may not be representative of patients being
selected for bridge to transplantation at other centers.
The present study analyzes data of a single center,
which is a subset of the Thoratec multicenter data.1 In
the multicenter study, blood urea nitrogen and previous
cardiac operation were found to be significant predic-
tors of survival. In our center, blood urea nitrogen was
not a significant factor, and although patients with pre-
vious operations had a lower survivorship, this differ-
ence did not reach statistical significance. However,
bilirubin also showed a trend toward significance (P =
.07) in the multicenter report.1 Patients with a pre-VAD
bilirubin concentration of more than 5 mg/dL had a
survival of only 33%, suggesting a considerable effect
of liver function on survival. Again, comparing the pre-
operative bilirubin levels, the patients in our subpopu-
lation had comparably worse preoperative hepatic
function (mean bilirubin averaging 5.8 mg/dL among
nonsurvivors compared with 3.6 mg/dL in the multi-
center group).
A consistent observation in all studies is that preop-
erative cardiac function (eg, cardiac index, left ventric-
ular ejection fraction, pulmonary capillary wedge pres-
sure) is not a significant predictor of survival, although
central venous pressure greater than 16 mm Hg was
included as a risk factor in the Columbia report.9 In our
analysis, patients with a lower cardiac index even
appeared to have a better chance of survival. A possible
explanation may be that the decision for support in
patients with extremely low cardiac output or in ven-
tricular fibrillation is being made immediately, where-
as those patients with long-standing borderline cardiac
function might remain in circulatory failure for too
long, leading to more severe end-organ damage.
The majority (88%) of the analyzed patients at our
center—and in fact all patients with impaired hepatic
function—have been supported with biventricular
VADs. Biventricular support has the potential not only
to restore blood flow to the liver, which is commonly
accepted as the main reason for ischemic hepatitis,4 but
also to directly relieve hepatic congestion, which is the
other pathophysiologic mechanism leading to hepatic
damage in cardiac failure.3 Our results are consistent
with the findings in another multicenter publication on
the Thoratec VAD,10 that patients requiring biventricular
support are more severely ill and have slightly reduced,
but still acceptable, survival.
Our results, although in only 4 of our patients, also
suggest that patients who received VADs after support
with other devices had reduced survival (only 1/4).
These patients could have had increased total bilirubin
levels related to hemolysis from the previous support.
If so, that could have had some impact on the data.
Variables of hepatic function. It is appropriate to
review the relevance of different liver function vari-
ables and to discuss their predictive value for liver
recovery, because the study population seems to be one
with a high degree of liver failure.
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Fig 3. Total bilirubin and AST in survivors and nonsurvivors
during the first 3 weeks after VAD implantation. Analyzed is
a subset of patients with a minimum VAD support of 7 days
(n = 18). Values are expressed as means ± standard error of
the mean.
Bilirubin. In severe hepatocellular disease caused by
congestive heart failure, particularly predominantly
right-sided failure, a certain elevation of bilirubin con-
centration is common. However, high values of more
than 5 mg/dL are rare and seen only in severe centrilob-
ular necrosis, especially in acute failure.3 Although clas-
sically one should expect mainly unconjugated (indirect)
hyperbilirubinemia owing to the difficulty of the liver
parenchyma to conjugate bilirubin, in most patients both
direct and indirect bilirubin levels rise. The reason for
the elevation of the direct fraction is a secretory abnor-
mality of unknown biochemical mechanism.16
In our study, the preoperative direct bilirubin fraction
appears to be a better predictor of patient survival than
total or indirect bilirubin. A possible reason might be
the additional rise of the indirect fraction by hemolysis,
which plays a role in hepatic congestion, but can also
be increased by therapies such as intra-aortic balloon
counterpulsation.
Transaminases. In isolated hepatic congestion, trans-
aminases rise only slightly. However in ischemic hepati-
tis, with a decrease in blood flow, a more than 5-fold rise
is frequent. This is strongly associated with the pathologic
finding of centrilobular necrosis.17 ALT is the more spe-
cific variable for liver recovery, because AST is also
released from damaged myocardium, skeletal muscle,
brain, and kidneys. However, in our patients AST and
ALT both were significant predictors for liver recovery.
LD. Inasmuch as all cells contain LD as an essential
enzyme, its rise is relatively nonspecific, although well
recognized in ischemic hepatitis in particular.4 In our
study, it was not a significant predictor for survival,
although it was a predictor for liver recovery. The LD
isoenzyme 5 fraction might have been an even better
marker for liver status, but no data were available.
AST/LD and ALT/LD ratio. Cassidy and Reynolds18
reported that the AST/LD ratio and, perhaps even more
important, the ALT/LD ratio can help differentiate
between viral and ischemic hepatitis. The authors sug-
gested that this could be due to less release of LD in
viral hepatitis, because only hepatocytes in zone 1 were
damaged, compared with all zones (although zone 3 in
particular) in ischemic injury. We tested these ratios in
our patient population with the underlying hypothesis
that the ratios would be higher in more severe hepato-
cellular disease. Both ratios were indeed higher in
patients whose livers did not recover, although the dif-
ference did not reach statistical significance.
Biliary tract enzymes. The reason for the rise of alka-
line phosphatase and gamma-glutamyl transferase levels
in heart failure is thought to be pressure-induced intra-
hepatic biliary obstruction, and it is therefore mainly
associated with elevated hepatic venous pressures.3
Both enzymes are rather mildly elevated even in severe
ischemic hepatitis and had no relevant predictive abili-
ty for survival or liver recovery in our patients.
Protein and albumin. Serum albumin levels reflect
long-term hepatic function. They often remain within
normal limits in ischemic hepatitis19 and do not corre-
late well with the degree of actual hepatic damage.3
Serum albumin levels can also be acutely influenced by
many factors (ie, the altered fluid status in heart failure
or iatrogenic factors). Protein and albumin therefore
did not show good predictive ability.
Prothrombin time. Prothrombin time is usually pro-
longed earlier than partial thromboplastin time because
of a deficiency of factor VII, the vitamin K–dependent
coagulation factor with the shortest half-life. Although
it is widely used clinically as a marker for severity of
liver damage, in our patients the difference between
survivors and nonsurvivors was not significant. Also,
no association between preoperative prothrombin time
and incidence of reoperation for bleeding was found.
Importance of patient selection and early VAD
support. In conclusion, pre-existing severe liver failure
was prevalent in our patient population being mechan-
ically bridged to transplantation with the Thoratec
VAD. Preoperative liver function was identified as the
most important predictor of survival, with total biliru-
bin and, in particular, its direct portion being the best
predictors. However, a few patients with highly
impaired liver function recovered during VAD support,
and thus no threshold value was found that should
absolutely lead to exclusion of a patient. In our experi-
ence, we have found that biventricular support is highly
recommended in extremely ill patients such as those
presented in this report. The encouraging survivals in
patients without liver failure (eg, 82% survival to trans-
plantation for patients with normal direct bilirubin lev-
els) reinforces the importance of early VAD interven-
tion to restore circulatory support before the onset of
irreversible organ failure.
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